IMMUNE NETWORK

  • 제5권1호
  • /
  • Pages.11-15
  • /
  • 2005
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지

Anti-CD3, CD16과 CD56 단일항체와 IL-2를 사용하여 활성화시킨 사람의 림프구

Human Activated Lymphocyte Treated with Anti-CD3, CD16, CD56 Monoclonal Antibody and IL-2

  • 홍선민 (Biocell 면역연구소) ;
  • 이동욱 (Biocell 면역연구소) ;
  • 강진구 (연세대학교 의과대학 소화기내과) ;
  • 김한수 (연세대학교 의과대학 소화기내과) ;
  • 조성훈 (Biocell 면역연구소)
  • 발행 : 2005.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Throughtout the last three decades, the therapy of leukemias and lymphoma has set the stage for curative cancer therapy in systemic malignant disease. This was the result of an integrated work of basic reaserch and clinical investigators leading to more aggressive albeit tolerable protocol of chemotherapy and radiotherapy. High dose therapy marks the most elaborated strategies in this field today. However, intensification of conventional therapeutic modalities as mentioned has to be based on new approaches and the exploration of new antineoplastic mechanisms. This insight has resulted in immune therapy of cancer. Among the cells of the immune system, natural killer (NK) cells and T cells are of major interest for the development of therapeutic strategies. Methods: Cytotoxicity to target cells was measured by LDH release method, Characterization of activated lymphocyte was measured by Flow cytometry analysis. Anti-CD3, 16, 56 monoclonal antibody and IL-2 were used for the activation of NK and T cell. The analysis of effect of activated lymphocyte, in vivo, were used by Balb/c nude mouse. Results and Conclusion: Cytotoxicity to K562 cells was significantly higher in the mixture group of NK and T cells than that of a group of activating T cells. The survivors and the rate of reduction of size of tumor craft of nude mouse group treatment with activated lymphocyte was higher than that of the group without treatment with activated lymphocyte. Therefore, this results are suggested that the activated lymphocytes by anti-CD3, CD16 and CD56 can reduce the malignancy effect of lymphoma.

키워드

참고문헌

  1. Boon T, Couline PG, van den Eynde B: Tumor antigen recognized by T cells. Immunol Today 18;267-268, 1997
  2. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18;175-182, 1997 https://doi.org/10.1016/S0167-5699(97)84664-6
  3. Berke G: The CTL kiss of death. Cell 81;9-12, 1995 https://doi.org/10.1016/0092-8674(95)90365-8
  4. Berke G: The Fas-based mechanism of lymphocytotoxicity. Hum Immunol 54;1-7, 1997 https://doi.org/10.1016/S0198-8859(97)00009-8
  5. Podack ER: Execution and suicide: cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways. Curr Opin Immunol 7;11-16, 1995 https://doi.org/10.1016/0952-7915(95)80023-9
  6. Liu CC, Walsh Cm, Young JD: Perforin: structure and function. Immunol Today 16;194-201, 1995 https://doi.org/10.1016/0167-5699(95)80121-9
  7. Azzoni L, Kamoun M, Salcedo TW, Kanakaraj P, Perussia B: Stimulation of Fc gamma RTIIIA results in phospholipase C-gamma 1 tyrosine phosphorylation and p56lck activation. J Exp Med 176;1745-1750, 1992 https://doi.org/10.1084/jem.176.6.1745
  8. Herberman RB: Cancer Immunotherapy with Natural Killer Cells. Seminars in Oncology 3;27-30, 2002
  9. Rosenberg SA: Lymphokine-activated killer cells. A new approach to the immunotherapy of cancer. J Natl Cancer Inst 75;595-601, 1985
  10. Morgan DA, Rusetti FW, Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrow. Sciences 193;1007-1009, 1976 https://doi.org/10.1126/science.181845
  11. Taga K, Yamaguchi A, Bloom ET, Tosato G: Target-induced death by apoptosis in human lymphokine-activated natural killer cells. Blood 87;2411-2418, 1996
  12. Henkart PA, Williams MS, Zacharchuk CM, Sarin A: Do CTL kill target cells by inducing apoptosis? Semin Immunol 9;135-144, 1997
  13. Stinchcombe JC, Grffiths GM: Regulated secretion from hemopoietic cells. J Cell BioI 147;1-6, 1999
  14. Klein C, Philippe N, Le Deist F, Fraitag S, Prost C, Durandy A, Fischer A, Griscelli C: Partial albinism with immunodeficiency (Griscelli syndrome). J Pediatr 125;886-895, 1994 https://doi.org/10.1016/S0022-3476(05)82003-7
  15. Rosenberg S, Lotze M, Muul L: A progress report on the treatment of 157 patients with advanced cancer using lvrnphokine-activated killer cells and interleukon-2 or high dose interleukin-2 alone. N Engl J Med 316;889-897, 1987 https://doi.org/10.1056/NEJM198704093161501
  16. Oda H, Oda H, Hayashi M, Cho SH: Adoptive lymphocyte immunotherapy in Non-Hodgkin's lymphoma (NHL). Biotherapy 18;333-338, 2004